|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
AIDS, adjunct |
|
Carcinoma, breast |
|
Carcinoma, endometrial |
| |
|
|
SIDE EFFECTS:
|
|
maculopapular rash |
|
malaise |
|
menstrual irregularity |
|
nausea/vomiting |
|
phlebitis |
|
pulmonary embolism |
|
rash (unspecified) |
|
thromboembolism |
|
weakness |
|
weight gain |
|
adrenocortical insufficiency |
|
alopecia |
|
appetite stimulation |
|
asthenia |
|
breakthrough bleeding |
|
carpal tunnel syndrome |
|
diabetes mellitus |
|
diaphoresis |
|
dizziness |
|
dyspepsia |
|
dyspnea |
|
edema |
|
elevated hepatic enzymes |
|
emotional lability |
|
fever |
|
heart failure |
|
hypercalcemia |
|
hyperglycemia |
|
hypertension |
|
hypotension |
|
hypothalamic-pituitary-adrenal (HPA) suppression |
|
impotence |
|
increased urinary frequency |
|
insomnia |
|
insulin resistance |
|
lethargy |
|
libido decrease |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
adrenal insufficiency |
|
breast cancer |
|
children |
|
Cushing's syndrome |
|
diabetes mellitus |
|
dysfunctional uterine bleeding |
|
elderly |
|
females |
|
hepatic disease |
|
hyperglycemia |
|
hypotension |
|
hypothalamic-pituitary-adrenal (HPA) suppression |
|
infection |
|
neoplastic disease |
|
renal impairment |
|
surgery |
|
thromboembolic disease |
|
thrombophlebitis |
|
vaginal bleeding |
|
|
ADULT DOSE:
|
|
Anorexia or
Cachexia or
Weight-loss, significant-
For patients with AIDS: Oral, 800 mg a day the first month, then 400 or 800 mg a day for three more months. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|